


MONDAY MARCH 30, 2020  
TUESDAY MARCH 31, 2020  
WEDNESDAY APRIL 1, 2020



# Immunotherapy for Infectious Diseases CONFERENCE 2020

March 30 to April 1, 2020

NOVEL WAYS TO FIGHT PATHOGENS



Corso Umberto I 33 - 28838 Stresa  
Lake Maggiore, ITALY  
C/O Hotel La Palma

[www.idimmunotherapy.com](http://www.idimmunotherapy.com)  
Email: [conference2020@unipv.it](mailto:conference2020@unipv.it)  
Phone: +39 (0)382 987725 - Ref: Prof. Livia Visai, Ph.D

# SOCIAL EVENT

**WELCOME: SUNDAY MARCH 29, 2020**

WELCOME from

**Livia Visai** (Department of Molecular Medicine of the University of Pavia)

**Michael Hust** (Technische Universität Braunschweig, Germany),

**Mireia Pelegrin** (INSERM, Montpellier, France)

**Luca Varani** (Institute for Research in Biomedicine, Bellinzona, Switzerland)

to the second edition of the International Conference "**Immunotherapy for infectious diseases conference - Novel ways to fight pathogens**" that it is held in Stresa, on Lake Maggiore, Italy, at Hotel La Palma ([www.hlapalma.it](http://www.hlapalma.it)) from the 29 March to the 1 April 2020.

Please visit the conference website: [www.idimmunotherapy.com](http://www.idimmunotherapy.com)



*ISOLA DEI PESCATORI*

**THE PLACE - STRESA**

**SUNDAY**  
**MARCH 29, 2020**

**3.00 PM**

meeting at Hotel La Palma  
for excursion to BORROMEO,  
BELLA AND PESCATORI  
ISLANDS and payment on site  
€ 40.00 per person

**3.30 PM**

starting excursion to  
BORROMEO, BELLA AND  
PESCATORI ISLANDS  
FREE dinner at any place  
around Stresa

**YOU ARE FREE AT**  
**DINNER AT YOUR OWN**

## 01

### SESSION 1 ANTIBODY-BASED DRUG DEVELOPMENT

Keynote Speaker: Davide Corti, Humabs BioMed SA a subsidiary of Vir Biotechnology

## 02

### SESSION 2 NANOMEDICINE AGAINST INFECTIOUS DISEASES

## 03

### SESSION 3 IMMUNOTHERAPY AGAINST EMERGING INFECTIOUS DISEASES

Keynote Speaker: Antonio Lanzavecchia, IRB, Switzerland

## 04

### SESSION 4 IMMUNOTHERAPY AGAINST VIRAL INFECTIONS

Keynote Speaker: Hugo Mouquet, Institut Pasteur, France

## 05

### SESSION 5 IMMUNOTHERAPY AGAINST BACTERIAL INFECTIONS

Keynote Speaker: Larry Zeitlin, Mapp Biopharmaceutical, USA

## 06

### SESSION 6 PRODUCTION AND REGULATORY CHALLENGES

## 07

### SESSION 7 3RS PRINCIPLES IN BIOTECHNOLOGICAL AND MEDICAL APPLICATIONS





## CONFERENCE HOSTS



The “Immunotherapy for Infectious Diseases Conference” brings together academia, small biotech, big pharma and regulatory bodies invested in the discovery of novel therapeutic strategies.

Infectious diseases remain a leading cause of morbidity and mortality worldwide necessitating novel and innovative therapeutics. Current and future challenges range from neglected diseases affecting the poorest countries to antimicrobial resistant pathogens in modern hospitals; from rare but deadly infections affecting few to the threat of potential global pandemics; from pathogens reaching new geographical areas due to climate changes to disease reemerging due to lack of vaccination coverage.



## OUR SPONSORS

**YUMAB****VIR**

preclinics

**HOEPLI****Bioidea2****BRUKER**

The ability of the human immune system to fight pathogens can be exploited for effective therapeutic strategies. Recombinant and further engineered antibodies can be used as active ingredients, as targeting agents to selectively deliver drugs or to establish novel vaccination strategies.

Bringing a novel therapy to the patients requires the combined effort of several players, all of which are brought together in the “Immunotherapy for Infectious Diseases Conference”, with world high caliber speakers and participants.

The congress is organized in the USA and Europe in alternating years with the aim to serve as a forum to exchange ideas and foster cross-disciplinary collaborations.

# MONDAY MARCH 30, 2020

7:30 – 8:30 AM **REGISTRATION AND BREAKFAST - Hotel La Palma**

8:30 – 8:45 AM **WELCOME REMARKS**

Livia Visai, Michael Hust, Mireia Pelegrin, Luca Varani and Luigi Calzolari

## SESSION 1

**ANTIBODY-BASED DRUG DEVELOPMENT: Main Room at Hotel La Palma**

**Moderators: Luca Varani and Man-Wah Tan**

**8:45 – 9:25 AM**

Infectious Diseases and Antibody Therapy

**KEYNOTE SPEAKER:** *Davide Corti, Humabs BioMed SA, a subsidiary of Vir Biotechnology*

**9:25 – 9:55 AM**

Development of lead molecules for antibody therapies

*André Frenzel, YUMAB, Germany*

**9:55 – 10:25 AM**

Recombinant snakebite antivenoms based on broadly-neutralizing oligoclonal antibodies

*Andreas Laustsen, Technical University of Denmark, Denmark*

**10:25 – 10:55 AM Break - Hotel La Palma**

**10:55 – 11:25 AM**

Development of Glyco-Humanized Polyclonal Antibodies from GGTA/CMAH Knockout donor animals

*Bernard Vanhove, CSO, Xenothera, France*

## SESSION 2

**NANOMEDICINE AGAINST INFECTIOUS DISEASES: Main Room at Hotel La Palma**

**Moderator: Luigi Calzolari**

**11:25 – 11:55 AM**

Nanotechnologies for vaccine development

*Donata Medaglini, University of Siena, Italy*

**11:55 – 12:25 PM**

Nanomedicine for HIV and Other Infectious Diseases  
*Jennifer Grossman, National Institute of Health, USA*

**12:30 – 2:00 PM Lunch and Poster Session - Hotel La Palma**

## SESSION 3

### IMMUNOTHERAPY AGAINST EMERGING INFECTIOUS DISEASES: Main Room at Hotel La Palma

**Moderators: Luca Varani and Larry Zetlin**

**2:00 – 2:30 PM**

Dissecting human antibody responses: useful, basic and surprising findings  
**KEYNOTE SPEAKER:** *Antonio Lanzavecchia, IRB, Switzerland*

**2:30 – 3:00 PM**

Anovel, fully-human monoclonal antibody against a host-cell protease inhibits the spread of respiratory viruses  
*Lisa Purcell, REGENERON, USA*

**3:00 – 3:30 PM**

Structure based rational design of neuroprotective antibodies against prion  
*Luca Varani, IRB, Switzerland*

**3:30 – 4:00 PM**

Passive Immunization 4.0 - Redirecting the tetanus immunity with sdAbs  
*Jonas Fuener, Preclinics GmbH, Germany*

**4:00 – 4:30 PM Break - Hotel La Palma**

**4:30 – 5:10 PM**

Broadly neutralizing monoclonal antibodies as therapeutics for patients hospitalized with severe influenza  
**KEYNOTE SPEAKER:** *Man-Wah Tan, Genentech, USA*

**5:10 – 5:40 PM**

*2 selected abstracts for oral presentations*

**8:00 PM Dinner - Hotel La Palma**

# TUESDAY MARCH 31, 2020

7:30 – 8:45 AM **REGISTRATION AND BREAKFAST - Hotel La Palma**

## SESSION 4

### IMMUNOTHERAPY AGAINST VIRAL AND BACTERIAL INFECTIONS: Main Room at Hotel La Palma

**Moderators: Mireia Pelegrin and Antonio Lanzavecchia**

**8:30 – 9:10 AM**

Antibody Memory B-cell Response to Hepatitis Viruses

**KEYNOTE SPEAKER:** *Hugo Mouquet, Institut Pasteur, France*

**9:10 – 9:40 AM**

Neutralizing human monoclonal antibodies against Dengue virus; towards commercialization

*Pongrama Ramasoota, Mahidol University, Bangkok, Thailand*

**9:40 – 10:10 AM**

Antibodies as immunotherapy in post-exposure prophylaxis for HIV

*Nancy Haigwood, Oregon Health and Science University, USA*

**10:10 – 10:40 AM**

Controlling opportunistic viral infections in transplant recipients: behind antivirals

*Fausto Baldanti, Policlinico San Matteo, IRCCS, Pavia, Italy*

**10:40 – 11:10 AM Break - Hotel La Palma**

**11:10 – 11:50 AM**

Monoclonal based countermeasures for filoviruses

**KEYNOTE SPEAKER:** *Larry Zeitlin, Mapp Biopharmaceutical, USA*

**11:50 – 12:20 PM**

*2 selected abstracts for oral presentations*

**12:30 – 2:00 PM Lunch and Poster Session - Hotel La Palma**



## SESSION 5

### IMMUNOTHERAPY AGAINST VIRAL AND BACTERIAL INFECTIONS: Main Room at Hotel La Palma

**Moderators: Micheal Hust and Mireia Pelegrin**

**2:00 – 2:30 PM**

Development of Monoclonal Antibodies by Phage Display: HlyE toxin antibodies  
*Theam Soon Lim, University Sains Malaysia (USM), Penang, Malaysia*

**2:30 – 3:00 PM**

Fighting pathogens and toxins with recombinant antibodies  
*Michael Hust, Technische Universität Braunschweig, Germany*

**3:00 – 3:30 PM**

Immunotherapy against bacterial infections  
*Matteo Pizzuto, Humabs BioMed SA a subsidiary of Vir Biotechnolgy*

**3:30 – 4:00 PM**

New therapeutic approaches to combat infectious diseases caused by *Helicobacter pylori*  
*Bernhard B. Singer, University Hospital Essen, Germany*

**4:00 – 4:00 PM Break - Hotel La Palma**

**4:30 – 5:00 PM**

Regulatory considerations in the development of biologic therapeutics  
*Sumathi Nambiar, U.S. Food and Drug and Administration, USA*

**5:00 – 5:30 PM**

Quality Assessment of Biologics and Biosimilars at Atomic Resolution  
*Anna Codina, Bruker Biospin*

**8:00 PM Dinner - Hotel La Palma**

# WEDNESDAY APRIL 1, 2020

7:30 – 8:45 AM **REGISTRATION AND BREAKFAST - Hotel La Palma**

## SESSION 6

**PRODUCTION AND REGULATORY CHALLENGES: Main Room at Hotel La Palma**

**Moderator: Luigi Calzolari**

**8:30 – 9:00 AM**

Immunotherapy of infectious diseases: regulatory pathways and expectations  
*Marisa Papaluca, former senior scientist, European Medicinal Agency*

**9:00 – 9:30 AM**

Prevention of Reoccurrence on TB: A new Vaccine on the Horizon  
*Leander Grode, VPM GmbH, Hannover, Germany*

## SESSION 7

**3RS PRINCIPLES IN BIOTECHNOLOGICAL AND MEDICAL APPLICATIONS: Main Room at Hotel La Palma**

**Moderator: Livia Visai**

**9:30 – 10:00 PM**

Non-Animal Models in Science: Challenges & Future Directions  
*Laura Gribaldo, Scientific Officer, European Commission Joint Research Centre, Italy*

**10:00 – 10:30 AM**

Replacing animals in regulated industries: Case studies in horse serum production and biocompatibility testing

*Jeff Brown, PETA International Science Institute, USA (3R and Infectious Disease)*

**10:30 – 11:00 AM Break - Hotel La Palma**

**11:00 – 11:30 AM**

Charité 3R: contributions to the 3Rs of the University Medicine Berlin

*Ida Retter, Charité, Berlin, Germany*

**11:30 – 12:30 PM**

*4 selected abstracts for oral presentation*

**12:30 -12:45 PM CONCLUSIONS AND REMARKS**



## Fausto Baldanti

**Full Professor, University of Pavia/Fondazione IRCCS Policlinico San Matteo, Pavia, Italy**

He graduated as Medicine Doctor, at Università degli Studi di Pavia, Italy in 1990; he received the Specialization in Infectious Diseases in 1995 at Università degli Studi di Pavia and the Specialization in Microbiology and Virology in 2004 at Università degli Studi di Padova.

He is the Head of the Molecular Virology Unit, at the Virology and Microbiology Dpt., Fondazione IRCCS Policlinico San Matteo, Pavia; he is Professor of Microbiology and Clinical Microbiology, at the University of Pavia; he is also Director of the Microbiology and Virology Specialization School, at the University of Pavia.

He is Professor of Clinical Virology at the Infectious Diseases Specialization School, at the Gastroenterology Specialization School, and at the Pathology Specialization School, at the University of Pavia.

He is Co-author of 310 papers published on international scientific journals indexed in Medline and Scopus and Co-author of more than 500 presentations (oral and poster) at Italian and International Congresses (h-index 50 (from Scopus)).



## Jeffrey Brown

**Advisor, PETA International Science Consortium Ltd.**

Jeffrey Brown is a science adviser with the PETA International Science Consortium Ltd. where he develops and supports the implementation of non-animal strategies in regulatory testing. His work focuses on collaboration with industry, researchers, and regulatory agencies to facilitate the use of non-animal methods in toxicity tests required for biologics and medical devices.

As a component of this work, he co-manages Science Consortium-funded research projects develop human recombinant antibodies intended to replace therapeutic equine serum products.

His work supports the Science Consortium's overall mission to advance the development, use, and global regulatory acceptance of the best in silico and in vitro testing approaches.



## Anna Codina

***Director, Pharmaceutical Business Unit, Bruker BioSpin, Bruker UK Limited***

Anna Codina has a degree in Chemistry and a PhD in Protein NMR from the University of Barcelona, Spain. During this time, she did several industrial placements at pharmaceutical industries, Pharmhispania, Spain and Genentech, SF, US, where he studied protein-antibody interactions.

She then moved to Cambridge, UK, to do a post-doc in structural biology at the MRC Laboratory of Molecular Biology, the same lab where Watson & Crick discovered the structure of the double helix of DNA.

After her post-doc Anna worked in the Analytical R&D department of Pfizer, UK, for 8 years, becoming proficient in low level impurity structure elucidation, reaction monitoring, qNMR and the preparation of regulatory documentation.

She joined Bruker in 2011 and since then she had several roles: Material Characterisation Laboratory Manager, Head of Applications of the Applied and Industrial division and Product Portfolio Manager.

Anna is currently the director of the pharmaceutical business Unit of Bruker BioSpin.



## Davide Corti

***SVP Antibody Research Humabs BioMed, a Subsidiary of Vir Biotechnology, Switzerland***

Dr. Davide Corti obtained his bachelor in Pharmaceutical Biotechnology at the University of Milan and his Ph.D. in Immunology at the University of Bern, followed by postdoctoral training in Antonio Lanzavecchia's laboratory at the Institute for Research in Biomedicine where he further developed and optimized two methods for the isolation of human monoclonal

antibodies out of memory B cells and plasma cells (Cellclone technologies).

In 2009 he was the Chief Scientific Officer at Humabs, where he leads a research group to isolate monoclonal antibodies against multiple infectious disease viral and bacterial agents.

Starting from 2012 he collaborated with MedImmune on the isolation of human antibodies against multiple target pathogens like Rhinovirus, Influenza B, Klebsiella and Staphylococcus.

His teams' efforts to date have generated three clinical stage candidates, MEDI8852 targeting Influenza A, mAb114 targeting Ebola virus and anti-CMV antibodies.

Dr. Corti has published more than 80 peer reviewed journal articles and holds 20 patents.

Humabs was acquired by Vir Biotechnology in 2017 to become its subsidiary in Bellinzona, Switzerland.

Dr. Davide Corti is now Senior Vice President, leading Antibody Research at Vir.



## André Frenzel

***Co-founder of YUMAB GmbH and CSO of the company, Braunschweig, Germany***

André Frenzel studied biology at Johannes Gutenberg University Mainz and received his PhD from the Leibniz Universität in Hannover.

In 13 years in the antibody field, André published more than 30 articles (including book chapters and reviews) on discovery and development of human antibodies and antibody phage display.

He works on the development of human and human-like antibodies for diagnostics and therapy with a focus on cancer and so-called difficult targets.

In 2009 he joined the working group of Prof. Dübel at University Braunschweig.

André is co-founder of YUMAB and acts as CSO for the company.



## Jonas Fünér

***General Manager of preclinics GmbH, Postdam, Germany***

In 2007 Jonas Fünér founded preclinics GmbH, a company focused on preclinical R&D with connected services and products.

He is managing director of preclinics in Potsdam and its subsidiaries Behring Campus Eystруп and BoNTANA Therapies. Jonas started as an animal technician in veterinary clinics and laboratories of the Free University Berlin.

In 1993 he went to the Forschungszentrum Jülich, where he was promoted to the Head of the Central Animal Laboratories.

Later he worked at the Max-Delbrück-Center on developing new methods for somatic gene transfer and was a founding member of bcd biomedical consulting & development GmbH in 1998, where he worked as a managing director till 2005.

During this time he started to immunize alpacas for the development of single domain antibodies.

Ever since Jonas and his team at preclinics are working on the topic of camelid immunizations and utilizing single domain antibodies.



## Laura Gribaldo

**Scientific Officer- European Commission, Directorate General Joint Research Centre (JRC)**

MD, PhD in Microbiology and Virology, she has thirty years of experience in the field of testing for safety assessment. As leader of the Applied Molecular Biology and Genomics competence group she set up and managed a transcriptomics platform for the development of standardized assays in toxicology and she was responsible to support a programme

ensuring harmonisation and validation of procedures in genetic testing for diagnostics purposes.

For the Public Health Unit, she worked on Rare Diseases, representing JRC at the EUCERD meetings for the establishment of the European platform for rare diseases registry.

Today, at the Chemicals Safety and Alternative Methods Unit, she works in the field of knowledge dissemination, education and training.



## Leander Grode

**Managing Director, Vakzine Projekt Management GmbH**

Dr. Leander Grode (1970) joined VPM in May, 2003.

As Manager he was responsible for all of VPM's projects until June, 2008. After being Director of Business Development since 2008 he became CSO and procurator of VPM in April 2013.

Since June 2019 Dr. Grode is Managing Director of VPM.

He studied biology in Giessen and Frankfurt/Main with focus on cell biology and zoology.

As an exchange student, he visited the University of California San Francisco in the Department of Biochemistry and Biophysics in the lab of Prof. John Watson.

He graduated in 1997 with a degree in biology at the Max Planck Institute of Biophysics in Frankfurt/Main in the Department of Molecular Membrane Biology under Prof. Hartmut Michel.

In the year 2000 he graduated as a PhD at the Max Planck Institute of Infection Biology in the Department of Immunology under Prof. Stefan H.E. Kaufmann.

The focus of his thesis was vaccine development against tuberculosis based on live carriers, such as salmonella or mycobacterium bovis BCG.

Between 2001 and 2003 Leander Grode was the coordinator of the vaccine development group at the MPI in the Department of Immunology.



## Jennifer Grossman

***PhD - Senior Scientific Program Manager - Vaccine Translational Research Branch - U.S. National Institute of Allergy and Infectious Diseases - Contractor***

Jennifer Grossman, PhD is a Contractor Senior Scientific Program Manager in the Vaccine Translation Research Branch (VTRB) in the Division of AIDS of the National Institute of Allergy and Infectious Disease (NIAID), one of the US National Institutes of Health (NIH).

She oversees the production of a portfolio of investigational HIV vaccine products, including antibodies, nanoparticles, protein immunogens, nucleic acids and adjuvants.

Jennifer provides nanotechnology subject matter expertise for R&D, manufacturing, analytics, formulation, Q/A and regulatory support for HIV vaccine products. Before joining the VTRB, Jennifer was at the National Cancer Institute (NCI), where she led alliance management for the Nanotechnology Characterization Lab (NCL). There, she established and managed productive collaborations within NCI, FDA, NIST and a network of drug development labs in industry and academia.

Jennifer's areas of scientific expertise include analytical methods for assessing drug delivery systems and modeling of nanoparticle structures and interactions. She has experience in a variety of issues related to nanotech drug development and regulation. Prior to joining the NCL in 2006, Jennifer conducted research in Physical Chemistry at the University of Maryland, where she focused on modeling and measuring protein motion under the guidance of Dr. David Fushman, Professor of Biochemistry. She holds a Ph.D. in Physical Chemistry, an M.S. in Chemical Physics and a B.S. in Physics.



## Nancy L. Haigwood

***Professor and Director, Oregon National Primate Research Center, Oregon Health & Science University***

Nancy L. Haigwood, Ph.D., is a Professor of Pathobiology & Immunology and Director of the Oregon National Primate Research Center at Oregon Health & Science University. She earned her Ph.D. in Microbiology & Immunology at UNC Chapel Hill and did postdoctoral work in virology at Johns Hopkins.

Since 1986, the focus of her research has been on HIV, in the areas of Envelope design and testing for vaccine development and on the role of antibodies in mother-to-child transmission in nonhuman primate models for AIDS.

Her group has shown that passively acquired neutralizing antibodies are powerful agents for change and viral clearance in SIV and SHIV infection.

She was elected a Fellow of the American Academy of Microbiology in 2014.





## Michael Hust

***Prof. Dr., Technische Universität Braunschweig, Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Braunschweig, Germany***

Michael studied biology at the Carl von Ossietzky Universität in Oldenburg, Germany, from 1993-1999.

He received his PhD from the Leibniz Universität in Hannover, Germany, in 2002.

Since end of 2002 he is working as group leader at the

Technische Universität Braunschweig, Germany.

In 2011, he finished his professorial dissertation (Habilitation, *venia legendi* for Biotechnology) and was appointed as Privatdozent (PD).

In 2014 he was appointed as professor for biotechnology.

He published more than 140 articles and filed seven patents in the field of antibody engineering and phage display.

He is working on the development of recombinant antibodies for proteome research, diagnostics and therapy with a focus on pathogens and toxins.

Another field of work is the identification of biomarkers of pathogens using ORFeome phage display.

He co-founded three biotech companies, the mAb-Factory GmbH in 2007, YUMAB GmbH ([www.yumab.com](http://www.yumab.com)) in 2012 and recently Norden Vaccines GmbH in 2019.



## Antonio Lanzavecchia

***Full Professor, IRB, Switzerland***

Antonio Lanzavecchia – Biosketch – is known for his work on antigen presentation by B cells and dendritic cells, for his studies on T cell activation and on the cellular basis of immunological memory, and for the development of novel methods to isolate human monoclonal antibodies.

Lanzavecchia was born in Italy and obtained a medical degree from the University of Pavia, where he specialized in pediatrics

and in infectious diseases.

From 1983 to 1999 he worked at the Basel Institute for Immunology and since 2000 is the founding director of the Institute for Research in Biomedicine in Bellinzona, Switzerland.

He is a Senior Vice President and Senior Research Fellow at Vir Biotechnology, Inc.

He has been professor of Immunology at the University of Genova and at the Swiss Federal Institute of Technology, ETH Zürich.

Lanzavecchia received the EMBO Gold Medal, the Cloetta Prize, the Robert Koch Prize, the Sanofi-Institut Pasteur prize and the Louis-Jeantet Prize and is a member of the EMBO and a foreign associate of the US National Academy of Sciences.



## Andreas Hougaard Laustsen

***Associate Professor, Technical University of Denmark,  
Department of Biotechnology and Biomedicine***

Associate Professor Andreas Hougaard Laustsen heads the Tropical Pharmacology Lab at the Department of Biotechnology and Biomedicine, Technical University of Denmark, and he is a Fellow of the Danish Royal Academy of Sciences and Letters (The Young Academy).

The Tropical Pharmacology Lab is an academic research group focusing on developing biotherapeutics and diagnostics against neglected tropical diseases: Andreas himself is specialized in antibody discovery, toxinology, antivenom, and neglected tropical diseases.

Andreas was an Advisor to the WHO's Working Group on Snakebite Envenoming, and he is a co-founder of the biotech companies Biosyntia, VenomAb, Antag Therapeutics, Chromologics, Bactolife, and VenomAid Diagnostics. Andreas is recognized as Denmark's Coolest Engineer, a Top 6 Academic Entrepreneur under 35 in Europe 2017, and he was on Forbes 30 under 30 list for 2017 and MIT Technology Review's list of the 35 Top Innovators under 35 in Europe 2017.



## Lim Theam Soon

***Senior Lecturer, Institute for Research In Molecular  
Medicine, University Saints Malaysia***

Theam Soon is a Penang born lad with a passion to try new things. He obtained his degree in resource chemistry from UNIMAS, Malaysia before continuing his postgraduate studies in Pharmaceutical Technology at USM.


He was then off to Germany where he carried out his doctoral thesis on antibody phage display at the Max Planck Institute for

Molecular Genetics and graduated with a doctorate degree in Molecular Biology from Freie Universitat Berlin. He returned to work at INFORMM, USM where he served as an academic staff and later as the Deputy Director.

Theam Soon is currently an Associate Professor heading a research group on antibody engineering at USM. He is also the principal researcher of the Antibody Program under the Higher Institutions Centre of Excellence program under the Malaysian Ministry of Education. He is working on the generation of new human antibody libraries with an emphasis on infectious diseases.

His work includes development of human antibodies for infectious disease research, diagnostics and therapy. Another field of work is the application of DNA structures for DNA sensing applications in diseases.

He has published several publications in peer-review journals and edited several books on antibody phage display technology. He is also active in industrial collaboration as well as academic research with projects related to antibody generation and modification.



## Man-Wah Tan

**Senior Director and Principal Scientist Head, Infectious Diseases and Microbiome Sciences Genentech**

Dr. Man-Wah Tan is currently the Senior Director and Principal Scientist of the Infectious Diseases Therapeutic Area at Genentech, a member of the Roche Group based in South San Francisco, California.

Prior to joining Genentech in 2010, Dr. Tan served on the faculty at the Genetics Department at Stanford University School of

Medicine for over 10 years.

Dr. Tan received his early trainings in the United Kingdom and the United States of America, receiving his MPhil from the University of Cambridge and PhD from Harvard University. Prior to moving to Stanford, he held an independent position as Harvard Junior Fellow at Harvard Medical School.

At Genentech, he heads the research groups responsible for the discovery and development novel therapeutics against hard-to-treat infectious agents of medical importance, with emphasis on viral and bacterial pathogens.

He has published over 60 research articles, and contributed to the discovery of 1 FDA-approved drug and 4 novel molecules in clinical development.



## Donata Medaglini

**PhD, Professor of Microbiology, University of Siena, Siena, Italy**

Donata Medaglini is Full Professor of Microbiology, Head of the Laboratory of Microbial Immunity in the Department of Medical Biotechnology at the University of Siena, Italy.

DM is the Italian Representative for “Nanotechnologies, Advanced Materials, Biotechnology, Advanced Manufacturing and Processing” in the Horizon 2020 EU Programme Committee.

She holds a PhD in Microbiology from the University of Genova. From 1992-1994 she was Research Associate in the Laboratory of Bacterial Pathogenesis and Immunology at The Rockefeller University (New York).

From 1996 till 2001 she was non-tenured Professor of Microbiology at the University of Siena.

In 2001-2003 she was National Expert at the European Commission, DG Research and Innovation.

Since 2003 is Professor of Microbiology at the University of Siena.

DM research activity is in the field of microbiology, vaccines and advanced immunization technologies, her recent studies are focussed on the modulation of primary immune response by different vaccine adjuvants and on the transcriptomic analysis of vaccine immune response.

She is author/co-author of several publications in international peer-reviewed journals.



## Hugo Mouquet

***Full professor, Head of the Humoral Immunology Lab, Institute Pasteur, Paris, France***

Dr. Mouquet earned a MS in Biochemistry & Molecular Biology and a PhD in Immunology from the University of Rouen (Normandy, France).

He performed his post-doctoral trainee in the laboratory of Michel C. Nussenzweig at the Rockefeller University (2007-2013), where he studied B-cell antibody response to HIV-1, isolated and

characterized HIV-1 bNAbs.

In 2013, Hugo started his group as a young investigator in the immunology department of the Institut Pasteur, supported by an ERC starting grant award. He currently heads the laboratory of Humoral Immunology at the Institut Pasteur.

His lab investigates the humoral responses to pathogens in humans with a focus on HIV-1, Hepatitis viruses and emerging infections, and a dual interest in basic and translational research.



## Sumathi Nambiar

***MD MPH, Director, Division of Anti-Infectives, Center for Drug Evaluation and Research, FDA***

Dr. Sumathi Nambiar is Director of the Division of Anti-Infective Products, Office of Antimicrobial Products, since July 2013.

Dr. Nambiar joined the Division of Anti-Infective Products in 2002. In her current role, Dr. Nambiar provides regulatory oversight for anti-infective products, including antibacterial, antifungal, and antiparasitic drugs.

Dr. Nambiar is board-certified in pediatrics and pediatric infectious diseases.

She completed her pediatric residency at the Inova Fairfax Hospital for Children, VA and her fellowship in pediatric infectious diseases at Children's National Medical Center, Washington DC. She received her MPH from The George Washington University School of Public Health.



## Marisa Papaluca

**MD (Former EMA Senior Scientific Adviser), School of Primary care and Public Health, Faculty of Medicine, Imperial College London**

Marisa Papaluca, MD, Specialist in Regulatory Science and Innovation, Former EMA Senior Scientific Advisor Scientific Committees Regulatory Science Strategy; Visiting Professor, Imperial College, School of Public Health, London, January 2020  
Marisa, graduated MD at the State university La Sapienza in

Rome (Italy) and then spent few years (1978-1994) in clinical immunology scientific research and clinical activity as internal medicine specialist, closely linked to the Academic clinical environment. Marisa joined in 1984 the Pharmaceuticals Department of the Italian Ministry of Health as medical director and since pioneered regulatory science work contributing to the creation of innovative approaches and tools including: the establishment in 1986 of the first Italian database to support pharmacovigilance Adverse Drug Reactions evaluation, in 1989 the format for National Assessment reports, in 1990 the Italian Office for Centralised Community Procedures (OCCP) to strengthen the participation to EU activities, and in 1993 the first multinational scientific advice for large clinical trials in EU.

Marisa joined the EMA in October 1994. Contributing to Agency foundations she drafted and implemented the main EMA centralised procedure for the preparation of the scientific opinions recommending the granting of Marketing Authorisations for the entire EU, along with the European Public Assessment Reports (EPARs).

After having covered various management positions<sup>1</sup> in July 2015 Marisa was appointed as the Senior Scientific Advisor of the European Medicines Agency and till retirement on 1 st April 2019, played a major role in the establishment of the European Innovation Offices Network (EU-IN), the methodology for the pilot EMA Regulatory Science Observatory<sup>2</sup> and the elaboration of the Regulatory Science Strategy 2025.



## Matteo Samuele Pizzuto

**Humabs BioMed, a Subsidiary of Vir Biotechnology, Switzerland**

Dr. Matteo Samuele Pizzuto obtained his Master Degree in Industrial Biotechnology at the University of Padua and his PhD in Virology and Oncolytic Virotherapy at the Imperial College London.

He has been working in Ilaria Capua's group at the FAO reference laboratory for avian influenza virus and has completed his training in reverse genetics at the Centre for Disease Control and Prevention in Atlanta (USA). In 2017 he joined Humabs Biomed where he has been working as PI in a project sponsored by the Bill and Melinda Gates Foundation focused on the development of orally deliverable secretory IgA for immunoprophylaxis of campylobacter infections.

Humabs was acquired by Vir Biotechnology to become its subsidiary in Bellinzona, Switzerland.

Dr. Pizzuto is now Senior Scientist at VIR.



## Lisa Purcell

***PhD, Clinical Sciences, Respiratory & Inflammation and Scientific Director, Secondary Education Programs, REGENERON***

Lisa Purcell joined Regeneron in 2008 and is a Senior Staff Scientist in Infectious Disease and Scientific Director. She received her PhD from McGill University and completed her Postdoctoral Training at Columbia University.

Dr. Purcell, along with her team, develops therapies for pathogens using Regeneron's novel technologies to translate 'science to medicine.' Dr. Purcell is actively involved in Regeneron's science education efforts including the Regeneron Science Talent Search, research mentorship efforts, the International and Westchester Science and Engineering Fair and STEM teacher programs. She also develops the science curriculum for the High School Research Mentorship and STEM Teacher Fellowship and has mentored many students from all of Regeneron's science education programs.



## Pongrama Ramasoota

***Director, Associate Professor, Center of Excellence for Antibody Research (CEAR), Head, Department of Social and Environmental Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand***

Director; Center of Excellence for Antibody Research (CEAR), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Collaborative Professor, Osaka University, Japan

[pongrama.ram@mahidol.ac.th](mailto:pongrama.ram@mahidol.ac.th)

Professor Dr. Ramasoota is lead investigator in the research project "Therapeutic human antibodies against 4 serotypes of Dengue virus" funded by Science and Technology Research Partnership for Sustainable Development (JST-JICA-SATREPS).

Dr. Ramasoota holds Doctor of Veterinary Medicine (DVM) and Master of Science and Ph.D. in Molecular biology from Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden.

He was awarded Outstanding Research and Invention Awards from 2008 Korea inventor Promotion Association (KIPA), 2008 International Federation of Inventor Association (IFIA), 2014 Taipei Invention show & Techno mart and National Research Council of Thailand (NRCT) in the years 2008-2010, 2014, 2016 and 2020.

He has published more than 70 publications with 5 patents.



## Ida Retter

**Charité 3R Head of Coordination, Charité  
Universitätsmedizin Berlin**

Ida Retter has a diploma in biochemistry and did her PhD at Werner Müllers lab, Department of Experimental Immunology at the Helmholtz Centre for Infection Research. After a postdoc at the lab of Dieter Jahn, Microbiology at Technische Universität Braunschweig, she moved towards research management.

Since 2018 she is head of office at Charité 3R, the 3R initiative of Charité Universitätsmedizin Berlin, where she coordinates measures for the development of alternatives to animal experiments and refinement.



## Bernard B Singer

**PD Dr. rer. nat. Universitätsklinikum Essen, Institut für  
Anatomie, Essen, Germany**

Since 2011 to present, Bernard B Singer is an associate professor at Institute of Anatomy, University Hospital, University Duisburg-Essen, in Germany.

Since 2016 to present, he is Co-founder and CEO of LeukoCom Biotech, Essen, in Germany.

Previously,

- he has also been a scientist, at Karolinska Institutet of Stockholm, in Sweden (1996 to 2000);
- he was a Scientific Director for antibody development at GenPat77 Biotech Company, in Berlin (2001 to 2002);
- Senior Scientist at the Institute for Biochemistry, Charite-Universitätsmedizin in Berlin (2003 to 2006 );
- Senior Scientist and lecturer at Institute of Anatomy, University Duisburg-Essen (2006 to 2011).

He is a DFG-funded immunologist/cell biologist/anatomist with a practice that focuses on the functional aspects of carcinoembryonic antigen-related cell adhesion molecules (CEACAMs).

He demonstrated the central role of CEACAM1 in orchestrating immune cell reactions and he generated a broad range of tools which made it easy and reliable to identify novel pathogens that specifically bind to CEACAMs.



## **Bernard Vanhove**

***Chief Scientific Officer/Operating Officer XENOTHERA, Nantes, France***

Bernard Vanhove holds a PhD in immunological sciences (University of Louvain, Belgium). He started an international scientific career at the Sandoz Vienna International Research Cooperation Center, Vienna, Austria and then spent 20 years at the INSERM/University of Nantes, France.

CNRS Research Director, he developed novel immunotherapies in transplantation, autoimmunity and immuno-oncology. He authored a hundred peer-reviewed scientific publications and applied for > 20 patents. In 2008, Bernard Vanhove co-founded Effimune and served as Chief Executive Officer, then became Chief Operating Officer of OSE Immunotherapeutics, where he contributed to introduce 3 biotherapeutics issued from his research team into clinical development. In 2019, he joined Xenothera as Chief Scientific and Operating Officer.



## **Luca Varani**

***Professor, IRB, Switzerland***

Luca Varani graduated in chemistry in Milan (Italy) and obtained a PhD at the prestigious MRC-Laboratory of Molecular Biology (Cambridge, UK) using molecular and structural biology to study RNA-protein interactions and their impact on gene expression. High caliber publications, culminated in the determination of the largest NMR structure available at the time, allowed him to move to Stanford with a “long term EMBO fellowship”, reserved to the

best young molecular biologists in Europe. In California, Luca Varani completed the first magnetic resonance study on TCR/pMHC complexes.

Since 2007 he leads the Structural Biology group of the Institute for Research in Biomedicine (Bellinzona, CH), investigating the interactions between pathogens and antibodies in rare and neglected diseases such as Dengue or Zika virus, Prion or rare form of Leukemias.

The NMR approach developed at Stanford was pushed forward at the IRB, where experimentally guided computational simulations yield the atomic structure of antibody/pathogen complexes. The approach allowed rationally modifying an antibody increasing its ability to neutralize Dengue virus by 50 fold utilizing, for the first time, only computational tools. More recently, the strategy allowed designing a bispecific antibody that prevents Zika virus escape mechanisms. Recent high impact publications appeared in journals such as Cell, Science, Nat. Cell. Biol. and PNAS.

The group uses a highly multidisciplinary approach, varying from structure determination to cellular experiments, computational biology, biophysics, protein and antibody production and engineering, nanoparticles and confocal microscopy.





## Larry Zeitlin

***Co-founder of Mapp Biopharmaceutical and LeafBio, Inc.,  
San Diego, CA, USA***

Larry Zeitlin received a B.A. in Biophysics and his doctorate in Reproductive Biology from The Johns Hopkins University. After serving as a Research Scientist at ReProtect, LLC (Baltimore, MD), and a Senior Scientist at Epicyte Pharmaceutical (San Diego, CA), together with Dr. Kevin Whaley, he co-founded Mapp Biopharmaceutical and LeafBio, Inc. (San Diego, CA).

He has been an adjunct faculty member of the Biodesign Institute at Arizona State University since 2004.

Larry's career focus has been on the development of monoclonal antibody based products to address unmet public health needs in infectious disease.

MONDAY MARCH 30, 2020  
TUESDAY MARCH 31, 2020  
WEDNESDAY APRIL 1, 2020



With the support of



With the patronage of



**Immunotherapy for  
Infectious Diseases  
CONFERENCE 2020**

**March 30 to April 1, 2020**

**NOVEL WAYS TO FIGHT PATHOGENS**



Corso Umberto I 33 - 28838 Stresa  
Lake Maggiore, ITALY  
C/O Hotel La Palma

[www.idimmunotherapy.com](http://www.idimmunotherapy.com)  
Email: [conference2020@unipv.it](mailto:conference2020@unipv.it)  
Phone: +39 (0)382 987725 - Ref: Prof. Livia Visai, Ph.D